I International: Top News And Analysis Guest Wednesday at 11:39 AM #1 Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028. Continue reading...
Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028. Continue reading...